EGFR and colorectal cancer: Data from xenograft experiments with colorectal cancer cell lines SW48 (RAS wildtype), HT-29 (RAS mutant), and SW620 (RAS mutant) presented by Mésange et al. indicated a superiority of a combined exposure to bevacizumab and erlotinib, an inhibitor of the EGFR tyrosine kinase, in comparison to bevacizumab alone [44].